Innovation–Innovation Tradeoffs in Drug Pricing image

Annals of Internal Medicine, October 11, 2016
Rachel Sachs (Academic Fellow alumna)


Read the full article

From the article:

The uproar over the price of the EpiPen is the latest episode in a longstanding controversy over drug pricing. A common concern is that proposed regulation of drug markets may reduce the rate of drug innovation and therefore decrease the number of new drugs that are brought to the marketplace. The editorialists discuss another important, but less frequently voiced, consideration: How could policy affect the composition of innovation, including the types of drugs that are brought to the marketplace?

Read the full article here!

bioethics fda health law policy pharmaceuticals public health rachel sachs regulation